Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira Reports Q1 2025 Revenue of $168.9 Million and Net Income of $4.8 Million

Mixed Impact 3 of 5 earnings Written later

Pacira BioSciences reported first quarter 2025 total revenues of $168.9 million, up from $167.1 million a year earlier, while GAAP net income fell to $4.8 million, or $0.10 per share, from $9.0 million, or $0.19 per share. The company reiterated its full-year 2025 revenue guidance of $725 million to $765 million, so shareholders see higher sales alongside lower reported profit.

Key points

  • Total revenues were $168.9 million versus $167.1 million a year earlier, with EXPAREL net product sales of $136.5 million versus $132.4 million.
  • GAAP net income was $4.8 million, or $0.10 per share, compared with $9.0 million, or $0.19 per share, in the first quarter of 2024.
  • Adjusted EBITDA was $44.1 million versus $44.6 million, and non-GAAP net income was $30.0 million versus $31.1 million.
  • Full-year 2025 total revenue guidance of $725 million to $765 million was reiterated, and the company cited a $300 million stock buyback program.

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECMay 8, 2025, 4:06 PM ET
Accession number0001396814-25-000060

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.